Tag Archives: Geulah Livshits

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NASDAQ: NTLA) and Concert Pharma (NASDAQ: CNCE)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Intellia Therapeutics (NTLA – Research Report) and Concert Pharma (CNCE – Research Report) with bullish sentiments. Intellia Therapeutics (NTLA) In a report

Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (NASDAQ: RCKT) and PerkinElmer (NYSE: PKI)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Rocket Pharmaceuticals (RCKT – Research Report) and PerkinElmer (PKI – Research Report). Rocket Pharmaceuticals (RCKT) Chardan Capital analyst Geulah Livshits reiterated a Buy rating on

Chardan Capital Initiates a Buy Rating on ARYA Sciences Acquisition (ARYA)

ARYA Sciences Acquisition (ARYA – Research Report) received a Buy rating and a $28.00 price target from Chardan Capital analyst Geulah Livshits yesterday. The company’s shares closed last Thursday at $13.55. According to TipRanks.com, Livshits is a 5-star analyst with

Chardan Capital Believes Replimune Group (NASDAQ: REPL) Still Has Room to Grow

In a report released yesterday, Geulah Livshits from Chardan Capital reiterated a Buy rating on Replimune Group (REPL – Research Report), with a price target of $29.00. The company’s shares closed last Wednesday at $20.19, close to its 52-week high

Chardan Capital Believes Intellia Therapeutics (NASDAQ: NTLA) Still Has Room to Grow

In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Intellia Therapeutics (NTLA – Research Report), with a price target of $57.50. The company’s shares closed last Monday at $19.78, close to its 52-week high

Crispr Therapeutics AG (CRSP) Receives a Buy from Chardan Capital

In a report released yesterday, Geulah Livshits from Chardan Capital reiterated a Buy rating on Crispr Therapeutics AG (CRSP – Research Report). The company’s shares closed last Friday at $64.58. According to TipRanks.com, Livshits is a 5-star analyst with an